Cargando…

A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom

BACKGROUND: Envenomation caused by multiple stings from Africanized honeybees Apis mellifera constitutes a public health problem in the Americas. In 2015, the Brazilian Ministry of Health reported 13,597 accidents (incidence of seven cases per 100,000 inhabitants) with 39 deaths (lethality of 0.25%)...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbosa, Alexandre Naime, Boyer, Leslie, Chippaux, Jean-Philippe, Medolago, Natalia Bronzatto, Caramori, Carlos Antonio, Paixão, Ariane Gomes, Poli, João Paulo Vasconcelos, Mendes, Mônica Bannwart, dos Santos, Lucilene Delazari, Ferreira, Rui Seabra, Barraviera, Benedito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356296/
https://www.ncbi.nlm.nih.gov/pubmed/28331487
http://dx.doi.org/10.1186/s40409-017-0106-y
_version_ 1782515799776296960
author Barbosa, Alexandre Naime
Boyer, Leslie
Chippaux, Jean-Philippe
Medolago, Natalia Bronzatto
Caramori, Carlos Antonio
Paixão, Ariane Gomes
Poli, João Paulo Vasconcelos
Mendes, Mônica Bannwart
dos Santos, Lucilene Delazari
Ferreira, Rui Seabra
Barraviera, Benedito
author_facet Barbosa, Alexandre Naime
Boyer, Leslie
Chippaux, Jean-Philippe
Medolago, Natalia Bronzatto
Caramori, Carlos Antonio
Paixão, Ariane Gomes
Poli, João Paulo Vasconcelos
Mendes, Mônica Bannwart
dos Santos, Lucilene Delazari
Ferreira, Rui Seabra
Barraviera, Benedito
author_sort Barbosa, Alexandre Naime
collection PubMed
description BACKGROUND: Envenomation caused by multiple stings from Africanized honeybees Apis mellifera constitutes a public health problem in the Americas. In 2015, the Brazilian Ministry of Health reported 13,597 accidents (incidence of seven cases per 100,000 inhabitants) with 39 deaths (lethality of 0.25%). The toxins present in the venom, which include melittin and phospholipase A(2), cause lesions in diverse organs and systems that may be fatal. As there has been no specific treatment to date, management has been symptomatic and supportive only. METHODS: In order to evaluate the safety and neutralizing capacity of a new apilic antivenom, as well as to confirm its lowest effective dose, a clinical protocol was developed to be applied in a multicenter, non-randomized and open phase I/II clinical trial. Twenty participants with more than five stings, aged more than 18 years, of both sexes, who have not previously received the heterologous serum against bee stings, will be included for 24 months. The proposed dose was based on the antivenom neutralizing capacity and the number of stings. Treatment will be administered only in a hospital environment and the participants will be evaluated for a period up to 30 days after discharge for clinical and laboratory follow-up. RESULTS: This protocol, approved by the Brazilian regulatory agencies for ethics (National Commission for Ethics on Research – CONEP) and sanitation (National Health Surveillance Agency – ANVISA), is a guideline constituted by specific, adjuvant, symptomatic and complementary treatments, in addition to basic orientations for conducting a clinical trial involving heterologous sera. CONCLUSIONS: This is the first clinical trial protocol designed specifically to evaluate the preliminary efficacy and safety of a new antivenom against stings from the Africanized honeybee Apis mellifera. The results will support future studies to confirm a new treatment for massive bee attack that has a large impact on public health in the Americas.
format Online
Article
Text
id pubmed-5356296
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53562962017-03-22 A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom Barbosa, Alexandre Naime Boyer, Leslie Chippaux, Jean-Philippe Medolago, Natalia Bronzatto Caramori, Carlos Antonio Paixão, Ariane Gomes Poli, João Paulo Vasconcelos Mendes, Mônica Bannwart dos Santos, Lucilene Delazari Ferreira, Rui Seabra Barraviera, Benedito J Venom Anim Toxins Incl Trop Dis Research BACKGROUND: Envenomation caused by multiple stings from Africanized honeybees Apis mellifera constitutes a public health problem in the Americas. In 2015, the Brazilian Ministry of Health reported 13,597 accidents (incidence of seven cases per 100,000 inhabitants) with 39 deaths (lethality of 0.25%). The toxins present in the venom, which include melittin and phospholipase A(2), cause lesions in diverse organs and systems that may be fatal. As there has been no specific treatment to date, management has been symptomatic and supportive only. METHODS: In order to evaluate the safety and neutralizing capacity of a new apilic antivenom, as well as to confirm its lowest effective dose, a clinical protocol was developed to be applied in a multicenter, non-randomized and open phase I/II clinical trial. Twenty participants with more than five stings, aged more than 18 years, of both sexes, who have not previously received the heterologous serum against bee stings, will be included for 24 months. The proposed dose was based on the antivenom neutralizing capacity and the number of stings. Treatment will be administered only in a hospital environment and the participants will be evaluated for a period up to 30 days after discharge for clinical and laboratory follow-up. RESULTS: This protocol, approved by the Brazilian regulatory agencies for ethics (National Commission for Ethics on Research – CONEP) and sanitation (National Health Surveillance Agency – ANVISA), is a guideline constituted by specific, adjuvant, symptomatic and complementary treatments, in addition to basic orientations for conducting a clinical trial involving heterologous sera. CONCLUSIONS: This is the first clinical trial protocol designed specifically to evaluate the preliminary efficacy and safety of a new antivenom against stings from the Africanized honeybee Apis mellifera. The results will support future studies to confirm a new treatment for massive bee attack that has a large impact on public health in the Americas. BioMed Central 2017-03-16 /pmc/articles/PMC5356296/ /pubmed/28331487 http://dx.doi.org/10.1186/s40409-017-0106-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Barbosa, Alexandre Naime
Boyer, Leslie
Chippaux, Jean-Philippe
Medolago, Natalia Bronzatto
Caramori, Carlos Antonio
Paixão, Ariane Gomes
Poli, João Paulo Vasconcelos
Mendes, Mônica Bannwart
dos Santos, Lucilene Delazari
Ferreira, Rui Seabra
Barraviera, Benedito
A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom
title A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom
title_full A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom
title_fullStr A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom
title_full_unstemmed A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom
title_short A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom
title_sort clinical trial protocol to treat massive africanized honeybee (apis mellifera) attack with a new apilic antivenom
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356296/
https://www.ncbi.nlm.nih.gov/pubmed/28331487
http://dx.doi.org/10.1186/s40409-017-0106-y
work_keys_str_mv AT barbosaalexandrenaime aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT boyerleslie aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT chippauxjeanphilippe aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT medolagonataliabronzatto aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT caramoricarlosantonio aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT paixaoarianegomes aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT polijoaopaulovasconcelos aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT mendesmonicabannwart aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT dossantoslucilenedelazari aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT ferreiraruiseabra aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT barravierabenedito aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT barbosaalexandrenaime clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT boyerleslie clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT chippauxjeanphilippe clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT medolagonataliabronzatto clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT caramoricarlosantonio clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT paixaoarianegomes clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT polijoaopaulovasconcelos clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT mendesmonicabannwart clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT dossantoslucilenedelazari clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT ferreiraruiseabra clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom
AT barravierabenedito clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom